Patents Assigned to Norvartis AG
-
Patent number: 9864108Abstract: The present invention general related to a reusable mold for making a contact lens comprises a first mold half having a first mold surface in contact with a polymerizable and/or crosslinkable silicone containing lens forming composition and a second mold half having a second mold surface in contact with the lens-forming composition, and the first mold half and the second mold half are configured to receive each other such that a cavity is formed between the first mold surface and the second mold surface. The cavity defines the shape of a contact lens to be molded. The reusable mold has at least one of the mold halves being made from an oxide glass comprising fluorine and/or fluoride. The mold made by oxide glass comprising fluorine and/or fluoride demonstrates improving mold cleanability with water based cleaning process.Type: GrantFiled: December 18, 2014Date of Patent: January 9, 2018Assignee: Norvartis AGInventors: Alice Weimin Liu, Burkhard Dietrich
-
Patent number: 9744228Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: GrantFiled: April 7, 2011Date of Patent: August 29, 2017Assignee: Norvartis AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20150164897Abstract: A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.Type: ApplicationFiled: July 25, 2013Publication date: June 18, 2015Applicant: Norvartis AGInventors: Giordano Caponigro, Darrin Stuart, Sunkyu Kim, Alice Loo, Scott Delach
-
Publication number: 20130195907Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: June 10, 2011Publication date: August 1, 2013Applicant: Norvartis AGInventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
-
Publication number: 20130130316Abstract: This invention relates to a cell culture process for the production of polypeptides in mammalian CHO cells characterized by one or more temperature and pH shifts which are adjusted in respect to their timing and step size to reduce cell death, increase product yield and improve product quality.Type: ApplicationFiled: April 25, 2011Publication date: May 23, 2013Applicant: Norvartis AGInventors: Christoph E. Joosten, Christian Leist, Jörg Schmidt
-
Publication number: 20120237545Abstract: A combination of ultrafiltration and HPLC is used to analyze influenza virus. This combination is able to quantify hemagglutinin (HA) and correlates well with single radial immunodiffusion (SRID) results, but can be performed without the delay of waiting for immunochemical SRID reagents.Type: ApplicationFiled: May 28, 2010Publication date: September 20, 2012Applicant: NORVARTIS AGInventors: Philip Dormitzer, Yingxia Wen, Paola Rinella, Gene Palmer
-
Publication number: 20120183611Abstract: The invention relates to a specific oral diclofenac formulation with beneficial both immediate-release and sustained-release properties.Type: ApplicationFiled: September 20, 2010Publication date: July 19, 2012Applicant: Norvartis AGInventor: Lance Shaw
-
Publication number: 20110021536Abstract: Crystalline forms or polymorphs of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.Type: ApplicationFiled: March 18, 2009Publication date: January 27, 2011Applicant: NORVARTIS AGInventors: Danielle Giron, Walter Hammerschmidt, Philippe Piechon, Johanne Polasek, Andreas Schreiner, Frank Stowasser
-
Patent number: 7638318Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: GrantFiled: January 19, 2006Date of Patent: December 29, 2009Assignee: Norvartis AGInventors: Paul L. Hallenbeck, Seshidar Reddy Police, Laura M. Hales, Carl M. Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
-
Publication number: 20090318445Abstract: The invention relates to novel compounds that are inhibitors of peptidyl deformylase (PDF). The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and uses of the compounds are also disclosed.Type: ApplicationFiled: December 28, 2006Publication date: December 24, 2009Applicants: NORVARTIS AG, NOVARTIS PHARMA GMBHInventors: Arkadius Pichota, Jeyaraj Duraiswamy, Zheng Yin, Thomas Hugo Keller, Mark Schreiber
-
Publication number: 20070191392Abstract: Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease or medical condition in which cathepsin K is implicated.Type: ApplicationFiled: April 23, 2007Publication date: August 16, 2007Applicant: NORVARTIS AGInventor: Martin MISSBACH
-
Publication number: 20050267129Abstract: Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease or medical condition in which cathepsin K is implicated.Type: ApplicationFiled: August 3, 2005Publication date: December 1, 2005Applicant: NORVARTIS AGInventor: Martin Missbach